Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | EIF4EBP1 | Q13541 | 10/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24001857 | 0.91 | GSK3B (0.38) | GSK3BCYP1A2CYP2D6PDE2AP2RX7 | |
| SCHEMBL24001917 | 0.91 | GSK3B (0.38) | GSK3BCYP1A2CYP2D6PDE2AP2RX7 | |
| SCHEMBL24001920 | 0.91 | GSK3B (0.38) | GSK3BCYP1A2CYP2D6PDE2AP2RX7 | |
| SCHEMBL24001694 | 0.88 | GSK3B (0.34) | GSK3BCYP1A2CYP2D6PDE2AEIF4EBP1 | |
| SCHEMBL30293379 | 0.88 | GSK3B (0.34) | GSK3BCYP1A2CYP2D6PDE2AEIF4EBP1 | |
| SCHEMBL24002211 | 0.88 | GSK3B (0.34) | GSK3BCYP1A2CYP2D6PDE2AEIF4EBP1 | |
| SCHEMBL24002208 | 0.88 | GSK3B (0.34) | GSK3BCYP1A2CYP2D6PDE2AEIF4EBP1 | |
| SCHEMBL25453304 | 0.83 | GSK3B (0.34) | GSK3BCYP1A2CYP2D6PDE2AEIF4EBP1 | |
| SCHEMBL31330503 | 0.81 | CNR1 (0.34) | GSK3BCYP1A2CYP2D6PDE2AEIF4EBP1 | |
| SCHEMBL30722571 | 0.81 | GSK3B (0.38) | GSK3BCYP1A2CYP2D6PDE2AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | AMGEN INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | AMGEN INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | MSR1, FPR2, CD14 | GSK3B 3411/4885CYP1A2 355/4885CYP2D6 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.